U.S., Dec. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07287150) titled 'A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer' on Dec. 11.
Brief Summary: This study will evaluate the efficacy and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen receptor pathway inhibitor (ARPi) or docetaxel in biomarker-selected participants with metastatic castrate-resistant prostate cancer (mCRPC) who have received one prior second-generation ARPi.
Study Start Date: March 31, 2026
Study Type: INTERVENTIONAL
Condition:
Metastatic Castration-Resistant Prostate Cancer
Intervention:
DRUG: Inavolisib...